<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">ophthalmology</journal-id><journal-title-group><journal-title xml:lang="ru">Офтальмология</journal-title><trans-title-group xml:lang="en"><trans-title>Ophthalmology in Russia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1816-5095</issn><issn pub-type="epub">2500-0845</issn><publisher><publisher-name>Ophthalmology</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18008/1816-5095-2015-4-18-26</article-id><article-id custom-type="elpub" pub-id-type="custom">ophthalmology-272</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Бромфенак (Броксинак) — новое слово в нестероидной противовоспалительной терапии (обзор литературы)</article-title><trans-title-group xml:lang="en"><trans-title>Bromfenac (Broksinak) — a new word in the nonsteroidal antiinflamatory drug (literature review)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Спиридонов</surname><given-names>Е. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Spiridonov</surname><given-names>E. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>ул. Ново-Садовая, 158, г. Самара, 443068</p></bio><bio xml:lang="en"><p>158, Novo-Sadovaya str., Samara, 443068</p></bio><email xlink:type="simple">evsp@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Государственное бюджетное учреждение здравоохранения «Самарская областная клиническая офтальмологическая больница им. Т.И. Ерошевского»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>State Budget Organization of Healthcare «Samara Regional Clinical Ophthalmologic Hospital named T.I. Eroshevsky»</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>08</day><month>01</month><year>2016</year></pub-date><volume>12</volume><issue>4</issue><fpage>18</fpage><lpage>26</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Спиридонов Е.А., 2016</copyright-statement><copyright-year>2016</copyright-year><copyright-holder xml:lang="ru">Спиридонов Е.А.</copyright-holder><copyright-holder xml:lang="en">Spiridonov E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.ophthalmojournal.com/opht/article/view/272">https://www.ophthalmojournal.com/opht/article/view/272</self-uri><abstract><p>Воспалительный процесс в  глазу может быть спровоцирован различными факторами  — аллергией, инфекцией, травмой (в  том числе, и хирургическим вмешательством), иметь серьёзные последствия и продолжаться даже после устранения причины, давая в исходе ухудшение зрения. С целью профилактики и купирования воспалительного процесса применяют два больших класса противовоспалительных веществ — кортикостероиды и нестероидные противовоспалительные средства (НПВС). Наряду с тем, что кортикостероиды являются «золотым стандартом» лечения воспаления органа зрения, они обладают рядом серьёзных побочных эффектов, таких как повышение внутриглазного давления и риск развития глаукомы, катаракты, активация бактериальной, вирусной и герпесвирусной инфекции. Положительными эффектами НПВС при  их  применении по  сравнению с  кортикостероидами являются стабильность внутриглазного давления (ВГД), анальгезирующий эффект и снижение риска вторичной инфекции. В офтальмологии в настоящее время применяют производные 3‑х классов: фенилуксусной кислоты — диклофенак, непафенак и бромфенак, индолуксусной кислоты — индометацин, гетероарилуксуной кислоты — кеторолак. Одними из последних синтезированных НПВС для офтальмологии являются амфенак и бромфенак. Бромфенак структурно идентичен амфенаку, но имеет атом брома в фенольном кольце, что придаёт чрезвычайно важные свойства молекуле бромфенака, отличая её от других НПВС. Во-первых, повышена липофильность молекулы и её пенетрационная способность относительно клеточных мембран различных тканей, включая ткани глаза, а во‑вторых, повысилась анальгезирующая и  противовоспалительная активность. При  исследовании ингибирующего действия бромфенака на  циклооксигеназу-2  в  эксперименте in vitro было показано, что  бромфенак сильнее диклофенака, амфенака и  кеторолака. Бромфенак эффективен для купирования всех признаков воспаления и полностью соответствует требованиям, предъявляемым к идеальному противовоспалительному препарату, а именно: хорошая пенетрационная способность, создание достаточной концентрации внутри глаза, активность в отношении циклооксигеназы, подавление развития макулярного отёка, хороший анальгезирующий эффект, минимальная токсичность, комфортность применения для пациентов. Бромфенак является единственным нестероидным противовоспалительным препаратом, который, обладая выраженным противовоспалительным действием, применяется один раз в день.</p></abstract><trans-abstract xml:lang="en"><p>Eye inflammation can be caused by different factors — allergies, infection, trauma (including surgery). It can have severe complications, last even after elimination the reason and cause the visual impairment as an outcome. Two main classes of anti-inflammatory agents (corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs)) are used for the prevention and relief of the inflammatory process. Along with the fact that corticosteroids are the «gold standard» treatment of inflammation in ophthalmology, they have a number of serious side effects such as increasing of intraocular pressure and the risk of developing glaucoma, cataracts, activation of bacterial, viral infection and herpes. The positive effects of NSAIDs in comparison with corticosteroids are stable intraocular pressure (IOP), analgesic effect and reduce the risk of secondary infection. The three classes of NSADs are currently used in ophthalmology. They are phenylacetic acid (diclofenac and bromfenac nepafenak), indole acetic acid (indomethacin) and geteroariluksunoy acid (ketorolac). The last synthesized NSAIDs for ophthalmology are amfenac and bromfenac. Bromfenac is effective for the relief of the inflammatory symptoms of and fully complies with the requirements for the ideal anti-inflammatory drugs such as good a penetration ability, creating a sufficient concentration inside the eye, the activity of cyclooxygenase, inhibiting the progress of macular edema, a good analgesic effect, minimal toxicity, comfort of use patients. Bromfenac is the only nonsteroidal antiinflammatory drugs, which is applied once a day and has a pronounced anti-inflammatory action.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>глаз</kwd><kwd>воспаление</kwd><kwd>кортикостероиды</kwd><kwd>негормональные противовоспалительные средства</kwd><kwd>бромфенак</kwd></kwd-group><kwd-group xml:lang="en"><kwd>eye inflammation</kwd><kwd>corticosteroids</kwd><kwd>non-hormonal anti-inflammatory agents</kwd><kwd>bromfenac</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">SN Serebrennikov, I.Zh. Seminsky [Pathophysiology of inflammation]. Irkutsk State Medical University, 2014.</mixed-citation><mixed-citation xml:lang="en">SN Serebrennikov, I.Zh. Seminsky [Pathophysiology of inflammation]. Irkutsk State Medical University, 2014.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">McGhee CN, Dean S, Danesh-Meyer H, Locally administered ocular corticosteroids: benefits and risks, Drug Saf, 2002;25:33‑55.</mixed-citation><mixed-citation xml:lang="en">McGhee CN, Dean S, Danesh-Meyer H, Locally administered ocular corticosteroids: benefits and risks, Drug Saf, 2002;25:33‑55.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Flach AJ, Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1‑11.</mixed-citation><mixed-citation xml:lang="en">Flach AJ, Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1‑11.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">El-Harazi SM, Ruiz RS, Feldman RM, et al., A randomized double-masked trial comparing ketorolac tromethamine 0,5%, diclofenac sodium 0,1% and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells, Ophthalmic Surg Lasers, 1998;29:539‑44.</mixed-citation><mixed-citation xml:lang="en">El-Harazi SM, Ruiz RS, Feldman RM, et al., A randomized double-masked trial comparing ketorolac tromethamine 0,5%, diclofenac sodium 0,1% and prednisolone acetate 1% in reducing post-phacoemulsification flare and cells, Ophthalmic Surg Lasers, 1998;29:539‑44.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts CW, Brennan KM, A comparison of topical diclofenac with prednisolone for postcataract inflammation, Arch Ophthalmol, 1995;113:725-7).</mixed-citation><mixed-citation xml:lang="en">Roberts CW, Brennan KM, A comparison of topical diclofenac with prednisolone for postcataract inflammation, Arch Ophthalmol, 1995;113:725-7).</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular Surgery News: Cataract patients may not need steroids after surgery,June 6, 2012</mixed-citation><mixed-citation xml:lang="en">Ocular Surgery News: Cataract patients may not need steroids after surgery,June 6, 2012</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Flach A, Nonsteroidal anti-inflammatory drugs. In: Tasman W (ed.), Duane’s Foundation jf Clinical Ophthalmology, Philadelphia: Lippincott, 1994;539‑44</mixed-citation><mixed-citation xml:lang="en">Flach A, Nonsteroidal anti-inflammatory drugs. In: Tasman W (ed.), Duane’s Foundation jf Clinical Ophthalmology, Philadelphia: Lippincott, 1994;539‑44</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Hyung Cho, Arash Mozayan, New Look at Ocular Inflammation Control — Powerful and Fast-acting Twice-daily Bromfenac for Novel Standard in the Treatment of Inflammation, European Ophthalmic Review, 2011;5 (1):20-6)</mixed-citation><mixed-citation xml:lang="en">Hyung Cho, Arash Mozayan, New Look at Ocular Inflammation Control — Powerful and Fast-acting Twice-daily Bromfenac for Novel Standard in the Treatment of Inflammation, European Ophthalmic Review, 2011;5 (1):20-6)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Asano S, Miyake K, OtaI, et al, reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0,1% and betamethasone 0,1%, J Cataract Refract Surg, 2008;34:57-63).</mixed-citation><mixed-citation xml:lang="en">Asano S, Miyake K, OtaI, et al, reducing angiographic cystoid macular edema and blood-aqueous barrier disruption after small-incision phacoemulsification and foldable intraocular lens implantation: multicenter prospective randomized comparison of topical diclofenac 0,1% and betamethasone 0,1%, J Cataract Refract Surg, 2008;34:57-63).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf EJ, Braunstein A, Shih C, et al., Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac, J Cataract Refract Surg, 2007;33:1546-9)</mixed-citation><mixed-citation xml:lang="en">Wolf EJ, Braunstein A, Shih C, et al., Incidence of visually significant pseudophakic macular edema after uneventful phacoemulsification in patients treated with nepafenac, J Cataract Refract Surg, 2007;33:1546-9)</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kessel L., Tendal B., Jorgensen K.J. et al. Post-cataract prevention of inflammation and macular edema by steroid and NSAID: a systematic review. Ophthalmology, 2014, Oct; 121 (10):1915-24).</mixed-citation><mixed-citation xml:lang="en">Kessel L., Tendal B., Jorgensen K.J. et al. Post-cataract prevention of inflammation and macular edema by steroid and NSAID: a systematic review. Ophthalmology, 2014, Oct; 121 (10):1915-24).</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Polansky JR, Weinreb RN, Steroids as anti-inflammatory agents. In: Sears ML (ed.), Pharmacology of the Eye, New York: Springer-Verlag, 1984;460-538).</mixed-citation><mixed-citation xml:lang="en">Polansky JR, Weinreb RN, Steroids as anti-inflammatory agents. In: Sears ML (ed.), Pharmacology of the Eye, New York: Springer-Verlag, 1984;460-538).</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular Surgery News. The science of NSAIDs, September 1, 2006.</mixed-citation><mixed-citation xml:lang="en">Ocular Surgery News. The science of NSAIDs, September 1, 2006.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular surgery News/Potency and pharmacokinetics of NSAIDs. February 15, 2006. The science of NSAIDs. September 1, 2006).</mixed-citation><mixed-citation xml:lang="en">Ocular surgery News/Potency and pharmacokinetics of NSAIDs. February 15, 2006. The science of NSAIDs. September 1, 2006).</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Donnenfeld ED, Donnenfeld A, Global experience with Xibrom (bromfenac ophthalmic solution) 0,09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug, Int Ophthalmol Clin, 2006;46:21-40).</mixed-citation><mixed-citation xml:lang="en">Donnenfeld ED, Donnenfeld A, Global experience with Xibrom (bromfenac ophthalmic solution) 0,09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug, Int Ophthalmol Clin, 2006;46:21-40).</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Flach AJ, Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1-11).</mixed-citation><mixed-citation xml:lang="en">Flach AJ, Topicalnonsteroidal anti-inflammatory drugs in ophthalmology, Int Ophthalmol Clin, 2002;42:1-11).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Samiy N, Foster CS, The role of nonsteroidal anti-inflammatory drugs in ocular inflammation, Int Ophthalmol Clin, 1996;36:195‑206.</mixed-citation><mixed-citation xml:lang="en">Samiy N, Foster CS, The role of nonsteroidal anti-inflammatory drugs in ocular inflammation, Int Ophthalmol Clin, 1996;36:195‑206.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Heier JS, Topping TM, Baumann W, et al., Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema, Ophthalmology, 2005;107:2034‑8, discussion 9.</mixed-citation><mixed-citation xml:lang="en">Heier JS, Topping TM, Baumann W, et al., Ketorolac versus prednisolone versus combination therapy in the treatment of acute pseudophakic cystoid macular edema, Ophthalmology, 2005;107:2034‑8, discussion 9.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">O’Brien TP, Emerging guidelines for use of NSAID therapy to oiptimize cataract surgery patient care, Curr Med Res Opin, 2005;21:1131-7).</mixed-citation><mixed-citation xml:lang="en">O’Brien TP, Emerging guidelines for use of NSAID therapy to oiptimize cataract surgery patient care, Curr Med Res Opin, 2005;21:1131-7).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Ahuja M, Dhake AS, Sharma SK et al., Topical ocular delivery of NSAIDs, AAPS J, 2008;10:229‑41.</mixed-citation><mixed-citation xml:lang="en">Ahuja M, Dhake AS, Sharma SK et al., Topical ocular delivery of NSAIDs, AAPS J, 2008;10:229‑41.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Bucci FA, Jr. Waterbury LD, Amico LM, Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0,4% (acular LS) and napafenac 0,1% (nеvanac) in patients undergoing phacoemulsification, Am J Ophthalmol, 2007;144:146‑7.</mixed-citation><mixed-citation xml:lang="en">Bucci FA, Jr. Waterbury LD, Amico LM, Prostaglandin E2 inhibition and aqueous concentration of ketorolac 0,4% (acular LS) and napafenac 0,1% (nеvanac) in patients undergoing phacoemulsification, Am J Ophthalmol, 2007;144:146‑7.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Walsh DA, Moran HW, Shamblee DA, et al., Antiinflammatory agents. 3. Synthesis and pharmacological Basis of 2‑amino-3‑benzoylphenylacetoc acid and analogues, J Med Chem, 1984;27:1379‑88.</mixed-citation><mixed-citation xml:lang="en">Walsh DA, Moran HW, Shamblee DA, et al., Antiinflammatory agents. 3. Synthesis and pharmacological Basis of 2‑amino-3‑benzoylphenylacetoc acid and analogues, J Med Chem, 1984;27:1379‑88.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Cho H, Wolf KJ, Wolf EJ, Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution, Clin Ophthalmol, 2009;3:199‑210.</mixed-citation><mixed-citation xml:lang="en">Cho H, Wolf KJ, Wolf EJ, Management of ocular inflammation and pain following cataract surgery: focus on bromfenac ophthalmic solution, Clin Ophthalmol, 2009;3:199‑210.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Sancilio LF, Nolan JC, Wagner LE, et al., The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac, Arzneimittelforschung 1987;37:513‑519.</mixed-citation><mixed-citation xml:lang="en">Sancilio LF, Nolan JC, Wagner LE, et al., The analgesic and antiinflammatory activity and pharmacologic properties of bromfenac, Arzneimittelforschung 1987;37:513‑519.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Data of file. Ista Pharmaceutical Inc).</mixed-citation><mixed-citation xml:lang="en">Data of file. Ista Pharmaceutical Inc).</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Yanni JM GG, Hellberg MR, Topically administrable composition containing 3‑benzoylphenilacetic acid derivative for treatment of ophthalmic inflammatory disorders, Alcon Laboratories, Inc., assignee. US Patent 5,475,034, 1995.</mixed-citation><mixed-citation xml:lang="en">Yanni JM GG, Hellberg MR, Topically administrable composition containing 3‑benzoylphenilacetic acid derivative for treatment of ophthalmic inflammatory disorders, Alcon Laboratories, Inc., assignee. US Patent 5,475,034, 1995.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Waterbury LD, Silliman D, Jolas T, Comparison of cycloxygenase inhibitory activity and ocular anti-inflammatory effects tromethamine and bromfenac sodium, Curr Med Res Opin, 2006;22:1133-40).</mixed-citation><mixed-citation xml:lang="en">Waterbury LD, Silliman D, Jolas T, Comparison of cycloxygenase inhibitory activity and ocular anti-inflammatory effects tromethamine and bromfenac sodium, Curr Med Res Opin, 2006;22:1133-40).</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Baklayan GA, Patterson HM, Song CK, et al. 24‑hour evaluation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits, J Ocul Pharmacol Ther, 2008;24:392-8).</mixed-citation><mixed-citation xml:lang="en">Baklayan GA, Patterson HM, Song CK, et al. 24‑hour evaluation of the ocular distribution of (14) C-labeled bromfenac following topical instillation into the eyes of New Zealand white rabbits, J Ocul Pharmacol Ther, 2008;24:392-8).</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Donnenfeld ED, Donnenfeld A, Global experience with Xibrom (bromfenac ophthalmic solution) 0,09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug, Int Ophthalmol Clin, 2006;46:21-40).</mixed-citation><mixed-citation xml:lang="en">Donnenfeld ED, Donnenfeld A, Global experience with Xibrom (bromfenac ophthalmic solution) 0,09%: the first twice-daily ophthalmic nonsteroidal anti-inflammatory drug, Int Ophthalmol Clin, 2006;46:21-40).</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Flach AJ, Cyclo-oxygenase unhibitors in ophthalmology, Surv Ophthalmol, 1992;36:259‑84</mixed-citation><mixed-citation xml:lang="en">Flach AJ, Cyclo-oxygenase unhibitors in ophthalmology, Surv Ophthalmol, 1992;36:259‑84</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Flach AJ The incidence, pathogenesis and treatment cystoid macular edema following cataract surgery, Trans Am Ophthalmol Soc, 1998;96:557-634).</mixed-citation><mixed-citation xml:lang="en">Flach AJ The incidence, pathogenesis and treatment cystoid macular edema following cataract surgery, Trans Am Ophthalmol Soc, 1998;96:557-634).</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Quinn CJ, Cystoid macular edema, Optom Clin, 1996;5:111-30).</mixed-citation><mixed-citation xml:lang="en">Quinn CJ, Cystoid macular edema, Optom Clin, 1996;5:111-30).</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Tranos PG, Wickremasinghe SS, Strangos NT, et al., Macular edema, Surv Ophthalmol, 2004;49:470‑90.</mixed-citation><mixed-citation xml:lang="en">Tranos PG, Wickremasinghe SS, Strangos NT, et al., Macular edema, Surv Ophthalmol, 2004;49:470‑90.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Colin J, The role of NSAIDs in the management of post-operative ophthalmic inflammation, Drugs, 2007;67:1291-308).</mixed-citation><mixed-citation xml:lang="en">Colin J, The role of NSAIDs in the management of post-operative ophthalmic inflammation, Drugs, 2007;67:1291-308).</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Sheufele TA HJ, Pseudophakic cystoid macular edema, Catarct Refract Surg Today, 2005;54‑7.</mixed-citation><mixed-citation xml:lang="en">Sheufele TA HJ, Pseudophakic cystoid macular edema, Catarct Refract Surg Today, 2005;54‑7.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Roberts CW, Pretreatment with topical diclofenac sodiumto decrease post-operative inflammation, Ophthalmology, 1996;103:636-9).</mixed-citation><mixed-citation xml:lang="en">Roberts CW, Pretreatment with topical diclofenac sodiumto decrease post-operative inflammation, Ophthalmology, 1996;103:636-9).</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Ray S, D’Amico DJ, Pseudophakic cystoid macular edema, Semin Ophthalmol, 2002;17:167-80).</mixed-citation><mixed-citation xml:lang="en">Ray S, D’Amico DJ, Pseudophakic cystoid macular edema, Semin Ophthalmol, 2002;17:167-80).</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Mentes J, Erakgun T, Afrashi F et al, incidence of cystoid macular edema after uncomplicated phacoemulsifikation, Ophthalmologica, 2003;217:408‑12.</mixed-citation><mixed-citation xml:lang="en">Mentes J, Erakgun T, Afrashi F et al, incidence of cystoid macular edema after uncomplicated phacoemulsifikation, Ophthalmologica, 2003;217:408‑12.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Ursell PG, Spalton DJ, Whitcup SM, et al., Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity, J Cataract Refract Surg, 1999;25:1492‑7.</mixed-citation><mixed-citation xml:lang="en">Ursell PG, Spalton DJ, Whitcup SM, et al., Cystoid macular edema after phacoemulsification: relationship to blood-aqueous barrier damage and visual acuity, J Cataract Refract Surg, 1999;25:1492‑7.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SJ, Bressler NM, Optical coherence tomography and cataract surgery, Curr Opin Ophthalmol, 2009;20:46-51).</mixed-citation><mixed-citation xml:lang="en">Kim SJ, Bressler NM, Optical coherence tomography and cataract surgery, Curr Opin Ophthalmol, 2009;20:46-51).</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Kim SJ, Flach AJ, Jampol LM, Nonsteroidal anti-inflammatory drugs in ophthalmology, Surv Ophthalmol, 2010;55:108‑33.</mixed-citation><mixed-citation xml:lang="en">Kim SJ, Flach AJ, Jampol LM, Nonsteroidal anti-inflammatory drugs in ophthalmology, Surv Ophthalmol, 2010;55:108‑33.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Lobo CL, Faria PM, Soares MA, et al. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30 (4):752‑760.</mixed-citation><mixed-citation xml:lang="en">Lobo CL, Faria PM, Soares MA, et al. Macular alterations after small-incision cataract surgery. J Cataract Refract Surg. 2004;30 (4):752‑760.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Miyake K, Prevention of cystoid macular edema after lens extraction by topical indometacin (I). A preliminary report, Albrecht Von Graefes Arch Klin Exp Ophthalmol, 1977;203:81‑8.</mixed-citation><mixed-citation xml:lang="en">Miyake K, Prevention of cystoid macular edema after lens extraction by topical indometacin (I). A preliminary report, Albrecht Von Graefes Arch Klin Exp Ophthalmol, 1977;203:81‑8.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">McColgin AZ, Raizman MB Efficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci. 1999;40: S289.</mixed-citation><mixed-citation xml:lang="en">McColgin AZ, Raizman MB Efficacy of topical Voltaren in reducing the incidence of postoperative cystoid macular edema. Invest Ophthalmol Vis Sci. 1999;40: S289.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">FitzGerald GA, Patron C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433‑442.</mixed-citation><mixed-citation xml:lang="en">FitzGerald GA, Patron C. The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001;345:433‑442.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assesment of anti-inflammatory efficacy. Inflammation.2000;24:357‑370.</mixed-citation><mixed-citation xml:lang="en">Gamache DA, Graff G, Brady MT, et al. Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assesment of anti-inflammatory efficacy. Inflammation.2000;24:357‑370.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Konstas AG, Maskaleris G, Gratsonidis, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye, 2000; 5:752‑756.</mixed-citation><mixed-citation xml:lang="en">Konstas AG, Maskaleris G, Gratsonidis, Sardelli C. Compliance and viewpoint of glaucoma patients in Greece. Eye, 2000; 5:752‑756.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Donnenfeld ED, Holland EJ, Stewart R, Grillon LR. For the Bromfenac study group</mixed-citation><mixed-citation xml:lang="en">Donnenfeld ED, Holland EJ, Stewart R, Grillon LR. For the Bromfenac study group</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Topical Xibrom 0,1% an investigational NSAIDs for post-cataractal surgery inflammation. Markedly decreases inflammation. Paper presented at: The annual ASCRS. April 15, 2005. Washington, DC).</mixed-citation><mixed-citation xml:lang="en">Topical Xibrom 0,1% an investigational NSAIDs for post-cataractal surgery inflammation. Markedly decreases inflammation. Paper presented at: The annual ASCRS. April 15, 2005. Washington, DC).</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Donnenfeld ED, Holland EJ, Stewart R et al. Topical Xibrom 0,1% an investigational NSAID, significantlyand rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest Ophthalmol Vis Sci. 2005; 46: E-abstract 791.</mixed-citation><mixed-citation xml:lang="en">Donnenfeld ED, Holland EJ, Stewart R et al. Topical Xibrom 0,1% an investigational NSAID, significantlyand rapidly decreased post-cataract surgery inflammation and reduced ocular pain. Invest Ophthalmol Vis Sci. 2005; 46: E-abstract 791.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Heier J, Cheetham JK, DegryseR. et al. Ketorolac tromethamine 0,5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253‑259.</mixed-citation><mixed-citation xml:lang="en">Heier J, Cheetham JK, DegryseR. et al. Ketorolac tromethamine 0,5% ophthalmic solution in the treatment of moderate to severe ocular inflammation after cataract surgery: a randomized, vehicle-controlled clinical trial. Am J Ophthalmol. 1999;127:253‑259.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Data on file at Alcon Laboratories, Inc)</mixed-citation><mixed-citation xml:lang="en">Data on file at Alcon Laboratories, Inc)</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Acular LS [Package insert]. Irvine, CA: Allergan, Inc.</mixed-citation><mixed-citation xml:lang="en">Acular LS [Package insert]. Irvine, CA: Allergan, Inc.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Personal communication with P. Cockrum, September 24, 2005.</mixed-citation><mixed-citation xml:lang="en">Personal communication with P. Cockrum, September 24, 2005.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular NSAIDs: a new option. Insert to Cataract &amp; Refractive Surgery Today, March, 2006, p.8.</mixed-citation><mixed-citation xml:lang="en">Ocular NSAIDs: a new option. Insert to Cataract &amp; Refractive Surgery Today, March, 2006, p.8.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular Surgery News: Ista announces positive results from phase 2 trial of lowdose bromfenac in dry eye disease, June 9, 2009.</mixed-citation><mixed-citation xml:lang="en">Ocular Surgery News: Ista announces positive results from phase 2 trial of lowdose bromfenac in dry eye disease, June 9, 2009.</mixed-citation></citation-alternatives></ref><ref id="cit57"><label>57</label><citation-alternatives><mixed-citation xml:lang="ru">Schechter BA. The evaluation of ketorolac (Acular LS) to improve patient comfort during the induction phase of cyclosporine A (Restasis ophthalmic emulsion) therapy. J Ocular Pharmacol Ther. In press.</mixed-citation><mixed-citation xml:lang="en">Schechter BA. The evaluation of ketorolac (Acular LS) to improve patient comfort during the induction phase of cyclosporine A (Restasis ophthalmic emulsion) therapy. J Ocular Pharmacol Ther. In press.</mixed-citation></citation-alternatives></ref><ref id="cit58"><label>58</label><citation-alternatives><mixed-citation xml:lang="ru">Gross J, Xibrom (bromfenac) reduces macular edema associated with vien occlusion, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3, 40th Meeting of thr Retina Society, Boston,2007.</mixed-citation><mixed-citation xml:lang="en">Gross J, Xibrom (bromfenac) reduces macular edema associated with vien occlusion, macular epiretinal membrane, diabetic retinopathy and age related macular degeneration. Poster F-3, 40th Meeting of thr Retina Society, Boston,2007.</mixed-citation></citation-alternatives></ref><ref id="cit59"><label>59</label><citation-alternatives><mixed-citation xml:lang="ru">Donnenfeld ED, Holland EJ, Stewart RH et al, Bromfenac ophthalmic solution 0,09% (Xibrom) for post-operative ocular pain and inflammation, Ophthalmology, 2007;114:1653‑62.</mixed-citation><mixed-citation xml:lang="en">Donnenfeld ED, Holland EJ, Stewart RH et al, Bromfenac ophthalmic solution 0,09% (Xibrom) for post-operative ocular pain and inflammation, Ophthalmology, 2007;114:1653‑62.</mixed-citation></citation-alternatives></ref><ref id="cit60"><label>60</label><citation-alternatives><mixed-citation xml:lang="ru">Endo N, Kato S, Haruyama K et al, Efficasy of bromfenac sodium in preventing cystoid macular oedemaafter cataract surgery in patient with diabetes, Acta Ophthalmol, 2010;88:896‑900.</mixed-citation><mixed-citation xml:lang="en">Endo N, Kato S, Haruyama K et al, Efficasy of bromfenac sodium in preventing cystoid macular oedemaafter cataract surgery in patient with diabetes, Acta Ophthalmol, 2010;88:896‑900.</mixed-citation></citation-alternatives></ref><ref id="cit61"><label>61</label><citation-alternatives><mixed-citation xml:lang="ru">Rho DS, Soll SM, Markovitz BJ, Bromfenac 0,09% versus diclofenac sodium 0,1% versus ketorolac tromethamine 0,5% in the treatment of acute pseudophakic cystoid macular edema, Invest Ophthalmo Vis Sci, 2006;47.</mixed-citation><mixed-citation xml:lang="en">Rho DS, Soll SM, Markovitz BJ, Bromfenac 0,09% versus diclofenac sodium 0,1% versus ketorolac tromethamine 0,5% in the treatment of acute pseudophakic cystoid macular edema, Invest Ophthalmo Vis Sci, 2006;47.</mixed-citation></citation-alternatives></ref><ref id="cit62"><label>62</label><citation-alternatives><mixed-citation xml:lang="ru">Cable M, Clinical outcomes of BROMDAY Versus Nepafenac, Presented at: Annual Meeting of American Siciety of Retinal Specialists, Boston, October 2011.</mixed-citation><mixed-citation xml:lang="en">Cable M, Clinical outcomes of BROMDAY Versus Nepafenac, Presented at: Annual Meeting of American Siciety of Retinal Specialists, Boston, October 2011.</mixed-citation></citation-alternatives></ref><ref id="cit63"><label>63</label><citation-alternatives><mixed-citation xml:lang="ru">Cable M, Review of Bromfenac Ophtalmic Solution 0,09% Once-daily (US Ophthalmic Review, 2012;5 (1):37‑9.</mixed-citation><mixed-citation xml:lang="en">Cable M, Review of Bromfenac Ophtalmic Solution 0,09% Once-daily (US Ophthalmic Review, 2012;5 (1):37‑9.</mixed-citation></citation-alternatives></ref><ref id="cit64"><label>64</label><citation-alternatives><mixed-citation xml:lang="ru">Keith Walter MD, Chris Komansky MSE, MSIV, Report on XXXI congress ESCRS, 2013.</mixed-citation><mixed-citation xml:lang="en">Keith Walter MD, Chris Komansky MSE, MSIV, Report on XXXI congress ESCRS, 2013.</mixed-citation></citation-alternatives></ref><ref id="cit65"><label>65</label><citation-alternatives><mixed-citation xml:lang="ru">Fujishima H., Fukagawa K. et al., Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis, J Ocul Pharmacol Ther, 2009 Jun;25 (3):265‑70.</mixed-citation><mixed-citation xml:lang="en">Fujishima H., Fukagawa K. et al., Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis, J Ocul Pharmacol Ther, 2009 Jun;25 (3):265‑70.</mixed-citation></citation-alternatives></ref><ref id="cit66"><label>66</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular Surgery News: Retina, September 15, 2011.</mixed-citation><mixed-citation xml:lang="en">Ocular Surgery News: Retina, September 15, 2011.</mixed-citation></citation-alternatives></ref><ref id="cit67"><label>67</label><citation-alternatives><mixed-citation xml:lang="ru">Ocular Surgery News: Retina, November, 2012.</mixed-citation><mixed-citation xml:lang="en">Ocular Surgery News: Retina, November, 2012.</mixed-citation></citation-alternatives></ref><ref id="cit68"><label>68</label><citation-alternatives><mixed-citation xml:lang="ru">Silverstein SM, Cable MG, Sadri E et al., Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group, Once daily dosing of bromfenac ophthalmic solution 0,09% for postoperative ocular inflammation and pain, Curr Med res Opin, 2011;27 (9):1693‑703.</mixed-citation><mixed-citation xml:lang="en">Silverstein SM, Cable MG, Sadri E et al., Bromfenac Ophthalmic Solution Once Daily (Bromday) Study Group, Once daily dosing of bromfenac ophthalmic solution 0,09% for postoperative ocular inflammation and pain, Curr Med res Opin, 2011;27 (9):1693‑703.</mixed-citation></citation-alternatives></ref><ref id="cit69"><label>69</label><citation-alternatives><mixed-citation xml:lang="ru">Lower-concentration NSAID reduces pain, inflammation after cataract surgery. Ophthalmology 2014;121 (1):25‑33, January 30, 2014.</mixed-citation><mixed-citation xml:lang="en">Lower-concentration NSAID reduces pain, inflammation after cataract surgery. Ophthalmology 2014;121 (1):25‑33, January 30, 2014.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
